← Leaderboards
Joseph D. Rosenblatt
University Of Rochester
$6,445,612
Attributed
$6,795,612
Total exposure
7
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $591.7K · FY2005–22$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$6,795,612 · 7
By mechanism
R01$3,546,162 · 3
P01$2,549,450 · 2
R44$400,000 · 1
R43$300,000 · 1
Top collaborators
- Rathin C Das2 shared
Most similar at University Of Rochester
Same institution · by research overlap
- David C Linehan$5,269,651
- David H Adler$2,091,939
- Sabine M Brouxhon$3,578,999
- Jean M Bidlack$6,851,551
- Patrick T Davies$15,134,391
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseTumorLeadT-LymphocyteImmuneMalignant NeoplasmsBasePropertyChemokineResistancePrimary NeoplasmCd4 Positive T LymphocytesChimeric ProteinsLaboratory MouseNeoplasm /Cancer ImmunotherapyIn VitroPlayGenetically Modified AnimalsMediatingSignal TransductionCellsIn VivoImmunityOvalbumin
Grant awards (25)
Development of Anti-EGFR-huEndo-P125A: A combined Vasculogenic Mimicry-Angiogenesis inhibitory therapeutic for Triple Negative Breast Cancer$400,000
R44 · FY2022 · CA
Combined Inhibition of Vasculogenic Mimicry and Angiogenesis in Ovarian Cancer using Antibody Fusion Protein$300,000
R43 · FY2019 · CA
Host Defense Regulation by HTLV-1$230,653
P01 · FY2013 · CA · contact PI
Host Defense Regulation by HTLV-1$246,665
P01 · FY2012 · CA · contact PI
Augmentation of Anti-Tumor Activity in the Absence of B Cells$260,587
P01 · FY2011 · CA · contact PI
Host Defense Regulation by HTLV-1$245,058
P01 · FY2011 · CA · contact PI
Augmentation of Anti-Tumor Activity in the Absence of B Cells$271,002
P01 · FY2010 · CA · contact PI
Host Defense Regulation by HTLV-1$258,459
P01 · FY2010 · CA · contact PI
Augmentation of Anti-Tumor Activity in the Absence of B Cells$275,962
P01 · FY2009 · CA · contact PI
Host Defense Regulation by HTLV-1$260,199
P01 · FY2009 · CA · contact PI
HSV Amplicon Activation of Innate and Adaptive Immunity$326,561
R01 · FY2008 · CA · contact PI
Augmentation of Anti-Tumor Activity in the Absence of B Cells$265,096
P01 · FY2008 · CA · contact PI
HSV Amplicon Activation of Innate and Adaptive Immunity$293,123
R01 · FY2007 · CA · contact PI
Augmentation of Anti-Tumor Activity in the Absence of B Cells$235,769
P01 · FY2007 · CA · contact PI
HSV Amplicon Activation of Innate and Adaptive Immunity$330,579
R01 · FY2006 · CA · contact PI
HSV Amplicon Activation of Innate and Adaptive Immunity$332,461
R01 · FY2005 · CA
HSV Amplicon Activation of Innate and Adaptive Immunity$336,837
R01 · FY2004 · CA
CHEMOKINE ENHANCED IMMUNE THERAPY OF LYMPHOMA$312,393
R01 · FY2002 · CA
ANTIBODY FUSION PROTEINS FOR THE THERAPY OF CANCER$142,878
R01 · FY2002 · CA
ANTIBODY FUSION PROTEINS FOR THE THERAPY OF CANCER$287,710
R01 · FY2001 · CA
CHEMOKINE ENHANCED IMMUNE THERAPY OF LYMPHOMA$220,404
R01 · FY2001 · CA
CHEMOKINE ENHANCED IMMUNE THERAPY OF LYMPHOMA$138,471
R01 · FY2001 · CA
CHEMOKINE ENHANCED IMMUNE THERAPY OF LYMPHOMA$345,257
R01 · FY2000 · CA
ANTIBODY FUSION PROTEINS FOR THE THERAPY OF CANCER$287,034
R01 · FY2000 · CA
INHIBITION OF HIV 1 USING A MUTANT TRNA PRIMER$192,454
R01 · FY2000 · AI